Home → E-shop → Nucleotides → Maribavir triphosphate – CAS 959379-16-9

Maribavir triphosphate – CAS 959379-16-9

Maribavir triphosphate – CAS 959379-16-9 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Maribavir triphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg		€ 4500	Stock
Do you want custom amount?				Custom amount

Amount

1 mg

€ 4500

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 959379-16-9

IUPAC name: ((2R,3S,4R,5R)-5-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate

Other names: Livtencity triphosphate

Molecular weight: 616.17 g/mol

Molecular formula: C₁₅H₂₂Cl₂N₃O₁₃P₃

InChI: InChI=1S/C15H22Cl2N3O13P3/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(22)12(21)11(31-14)5-30-35(26,27)33-36(28,29)32-34(23,24)25/h3-4,6,11-14,21-22H,5H2,1-2H3,(H,18,19)(H,26,27)(H,28,29)(H2,23,24,25)/t11-,12-,13-,14-/m1/s1

Description

Maribavir triphosphate is the active metabolite of Maribavir, an antiviral drug used to treat post-transplant cytomegalovirus (CMV). Maribavir is a cytomegalovirus pUL97 kinase inhibitor that acts by inhibiting the activity of the human cytomegalovirus enzyme pUL97, halting virus multiplication.

Chemicals are distributed worldwide

Buy Maribavir triphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Marty, F. M., Ljungman, P., Papanicolaou, G. A., Winston, D. J., Chemaly, R. F., Strasfeld, L., … & Boeckh, M. (2011). Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. The Lancet infectious diseases, 11(4), 284-292.